Apricus Biosciences Confirms Clinical Strategy for Novel Treatment for Symptomatic Secondary Hypogonadism Fispemifene
December 01, 2015 at 12:44 PM EST
Apricus Biosciences, Inc. (Nasdaq: APRI) today reaffirmed its regulatory and clinical strategy for the development of fispemifene in ...